首页> 外文OA文献 >Exploring the Role of N(6)-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ∇
【2h】

Exploring the Role of N(6)-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ∇

机译:探索N(6) - 取代基在强效双作用5'-C-乙基四唑腺苷衍生物中的作用:小鼠的合成,结合,功能测定和抗伤害作用∇

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Structural determinants of affinity of N(6)-substituted-5'-C-(ethyltetrazol-2-yl)adenosine and 2-chloroadenosine derivatives at adenosine receptor (AR) subtypes were studied with binding and molecular modeling. Small N(6)-cycloalkyl and 3-halobenzyl groups furnished potent dual acting A1AR agonists and A3AR antagonists. 4 was the most potent dual acting human (h) A1AR agonist (Ki = 0.45 nM) and A3AR antagonist (Ki = 0.31 nM) and highly selective versus A2A; 11 and 26 were most potent at both h and rat (r) A3AR. All N(6)-substituted-5'-C-(ethyltetrazol-2-yl)adenosine derivatives proved to be antagonists at hA3AR but agonists at the rA3AR. Analgesia of 11, 22, and 26 was evaluated in the mouse formalin test (A3AR antagonist blocked and A3AR agonist strongly potentiated). N(6)-Methyl-5'-C-(ethyltetrazol-2-yl)adenosine (22) was most potent, inhibiting both phases, as observed combining A1AR and A3AR agonists. This study demonstrated for the first time the advantages of a single molecule activating two AR pathways both leading to benefit in this acute pain model.
机译:通过结合和分子建模研究了N(6)-取代的5'-C-(乙基四唑-2-基)腺苷和2-氯腺苷衍生物在腺苷受体(AR)亚型上的亲和力的结构决定因素。小的N(6)-环烷基和3-卤代苄基可提供有效的双作用A1AR激动剂和A3AR拮抗剂。 4是最有效的双作用人(h)A1AR激动剂(Ki = 0.45 nM)和A3AR拮抗剂(Ki = 0.31 nM),对A2A具有高度选择性。 11和26对h和大鼠(r)A3AR均最有效。所有N(6)-取代的5'-C-(乙基四唑-2-基)腺苷衍生物均被证明是hA3AR的拮抗剂,但在rA3AR上是激动剂。在小鼠福尔马林测试中评估了11、22和26的镇痛效果(A3AR拮抗剂被阻滞,A3AR激动剂被强效)。 N(6)-甲基-5'-C-(乙基四唑-2-基)腺苷(22)最有效,抑制两个相,如结合A1AR和A3AR激动剂所观察到的。这项研究首次证明了单个分子激活两条AR通路的优势,都可在这种急性疼痛模型中受益。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号